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704Deﬁning the Natural History of Uremic
Cardiomyopathy in Chronic Kidney Disease
The Role of Cardiovascular Magnetic ResonanceABSTRACTChronic kidney disease (CKD) is an under-recognized, highly prevalent cardiovascular (CV) risk factor affecting 1 in
7 adults. Large epidemiological studies have clearly established a graded association between the severity of CKD and CV
event rates. Although patients with end-stage renal disease who are undergoing dialysis are at greatest CV risk, the
disease process is evident in the early stages of CKD with glomerular ﬁltration rates as high as 75 ml/min/1.73 m2. Indeed,
these patients are at least 6 times more likely to die of CV disease than to reach end-stage CKD. Thus, the major impact of
CKD on the population and the healthcare budget is not that of providing renal replacement therapy but the cost of death
and disability from premature CV disease.
Although end-stage CKD is characterized by a clustering of conventional atherosclerotic risk factors, it has little
association with CV event rates. This is reﬂected in disproportionate levels of sudden cardiac death, heart failure,
and stroke, rather than myocardial infarction. Thus it appears that nonatherosclerotic processes, including left ven-
tricular hypertrophy and ﬁbrosis, account for most of the excess CV risk. Over the past decade, the use of cardiac
magnetic resonance in CKD has brought about an improved understanding of the adverse CV changes collectively
known as uremic cardiomyopathy. The unique ability of cardiac magnetic resonance to provide a comprehensive
noninvasive examination of cardiac structure and function, arterial function, myocardial tissue characterization
(T1 mapping and inversion recovery imaging), and myocardial metabolic function (spectroscopy) is ideally suited
to characterize the phenotype of CV disease in CKD and to provide insight into the mechanisms leading to
uremic cardiomyopathy. Concerns relating to an association between gadolinium contrast agents and nephrogenic
systemic ﬁbrosis in dialysis recipients have led to the use of lower doses and lower-risk gadolinium agents that
appear to minimize this risk. (J Am Coll Cardiol Img 2014;7:703–14) © 2014 by the American College of Cardiology
Foundation.SEE PAGE 729
T he term chronic kidney disease (CKD) en-compasses all renal disease states fromthe earliest stages through to end-stage
renal disease (ESRD) requiring renal replacement
therapy (Table 1). Although the cardiovascular risk
of patients with ESRD is extreme, the major burden
lies in early-stage CKD, which is highly prevalent.
Early-stage CKD affects 10% to 16% of adults
in developed nations with a prevalence that is
increasing rapidly as the population ages and as rates
of obesity, diabetes, and hypertension continue to
rise (1). Although most of the original studies exam-
ining cardiovascular disease in CKD focused on pa-
tients with ESRD, more recent large studies have
demonstrated that cardiovascular risk increases very
early in the natural history of CKD, probably at a
glomerular ﬁltration rate (GFR) level of approximately
75 ml/min/1.73 m2 when serum creatinine may still
be within the normal range (2). The risk of cardio-
vascular death in early-stage CKD far exceeds the
risk of progressing to dialysis; therefore, treatment
should be focused at least as much on reducing thisrisk as on reducing the rate of progression of renal
disease.Epidemiological studies suggest that most cardio-
vascular deaths that occur in ESRD are attributable
to sudden cardiac death, arrhythmia, or congestive
heart failure, and relatively few deaths result from
coronary artery disease and myocardial infarction
(3). Although traditional cardiovascular risk factors
are more common in patients with CKD, these
fail to account for the elevated risk. This ﬁnding
suggests that the mechanistic processes driving
cardiovascular disease in CKD may differ from those
in the general population (Table 2). Nonatheromatous
processes such as arteriosclerosis, arterial stiffening,
and abnormalities of cardiac structure appear to pre-
dominate and could explain why standard cardio-
vascular disease–modifying drugs such as statins
have failed to have the same impact on car-
diovascular mortality in CKD as they do in the
general population (4). Thus, detection of these
TABLE 1 Cardiovascular Risk Odds Ratio According to Stage of CKD*
Stage
Estimated GFR
(ml/min/1.73 m2)
Cardiovascular Risk
(Odds Ratio)
1 >90† Dependent on degree of proteinuria
2 30–89† 1.5
3 30–59 2–4
4 15–29 4–10
5 <15 10–50
ESRD Dialysis 20–1000
*The increase in risk in comparison with people free from chronic kidney disease (CKD) depends on
the age of the population studied: the younger the subject, the higher the relative risk. Micro-
albuminuria increases the cardiovascular risk by an additional 2- to 4-fold. †Evidence of functional
or structural kidney abnormalities for $3 months deﬁned as abnormal renal biopsy, markers of
renal damage (persistent proteinuria, albuminuria, hematuria) or structural renal abnormality on
imaging studies. Adapted with permission from Schiffrin et al. (50).
ESRD ¼ end-stage kidney disease; GFR ¼ glomerular ﬁltration rate.
ABB R E V I A T I O N S
AND ACRONYMS
AD = aortic distensibility
CKD = chronic kidney disease
CMR = cardiac magnetic
resonance
eGFR = estimated glomerular
ﬁltration rate
ESRD = end-stage renal
disease
Gd = gadolinium
GFR = glomerular ﬁltration
rate
LGE = late gadolinium
enhancement
LV = left ventricular
LVH = left ventricular
hypertrophy
NSF = nephrogenic systemic
ﬁbrosis
TTE = transthoracic
echocardiography
UC = uremic cardiomyopathy
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705abnormalities of cardiac and vascular structure and
function is pivotal in the diagnosis, risk stratiﬁcation,
and monitoring of cardiovascular disease in CKD
(Table 3).
REDEFINING UREMIC CARDIOMYOPATHY
WITH CARDIAC MAGNETIC RESONANCE
In the 1980s, echocardiographic studies identiﬁed
common adverse changes in cardiac structure and
function associated with ESRD that were often
termed uremic cardiomyopathy (UC) (5). The presence
of these abnormalities, including left ventricular
hypertrophy (LVH), left ventricular (LV) dilation,
and LV systolic dysfunction, is associated with
worse cardiovascular outcome (6). The role of trans-
thoracic echocardiography (TTE) in diagnosis and
surveillance of heart disease in CKD is however
limited by the wide variability in assessment of
LV mass and lack of tissue characterization. Where
LV volumes are subject to change, for example in pa-
tients undergoing dialysis, interoperator variability
becomes unacceptable (as high as 40.1  22.1 g com-
pared with 2.4  4.6 g using CMR) (7). Although it
is possible to standardize the performance of TTE to
a speciﬁc time period after dialysis, TTE consistently
overestimates LV mass. Almost 48% of patients with
LVH can be reclassiﬁed as normal when assessed
using CMR criteria (Fig. 1) (8).
Despite this reclassiﬁcation, abnormalities of car-
diac structure or function are still frequent when CMR
is performed in ESRD. In a pivotal study of 134 pa-
tients who had been undergoing renal replacement
therapy for an average duration of 12 months, CMR
with gadolinium (Gd) contrast agents was performed
on the post-dialysis day or at dry weight for perito-
neal dialysis (9). The most frequent abnormality
detected was LVH (72%), with comparatively low
rates of LV dilation (11%) and LV systolic dysfunction
(8%). The importance of an accurate, volume-
independent measure of cardiac mass is paramount,
given that LVH is a strong independent risk factor
for mortality, cardiac arrhythmia, and heart failure
in patients undergoing dialysis (10). However, the
categorization of patients as having LVH is not a
biological dichotomy; LV mass is a continuous vari-
able with a graded relationship with cardiovascular
risk. This is reﬂected by improved cardiovascular
outcomes with LV mass regression when both LV
mass and blood pressure are within the “normal
range” and serves to emphasize the role of CMR in
accurately quantifying LV mass (11). Indeed, previous
echocardiographic studies attributed the reduction in
mortality following active treatment of anemia (12)and renal transplantation to a reduction
in LV mass (13). When such studies were
repeated using serial CMR, however, regres-
sion of LV mass with renal transplantation
was not conﬁrmed (14). These negative ﬁnd-
ings on CMR cast doubt on the reversibility of
LV mass in ESRD and serve to refocus treat-
ment to the earlier phases of CKD, when
prevention of LVH may be more successful.
The features of UC have been described
comprehensively in cross-sectional studies
of patients with ESRD, but far less is
known about the onset or natural history of
such changes in early-stage CKD. In a cross-
sectional echocardiographic study of 3,487
U.S. patients, Park et al. (15) reported preva-
lence rates of LVH of 32%, 48%, 57%, and 75%
for estimated GFR (eGFR) categories $60, 45
to 59, 30 to 44, and <30 ml/min/1.73 m2,
respectively. This apparent linear association
between the severity of CKD and increased
LV mass was demonstrated using measure-
ment of cystatin C to estimate GFR, which has
the advantage of being independent of muscle mass.
Although no such graded relationship has been
conﬁrmed using CMR, the rates of increased LV mass
are similar to those seen in cross-sectional CMR
studies involving more than 200 patients with
stages 2, 3, and 4 CKD without a history of diabetes
or cardiovascular disease (16,17). Edwards et al. (17)
reported that one-third of patients had signiﬁcantly
elevated LV mass despite a mean GFR of 51 ml/min/
m2 compared to sex- and age-matched control
subjects. These data are important in emphasizing
that adverse cardiac structural changes occur early
in the course of CKD when creatinine is frequently
near normal and before biochemical changes of
uremia are present. Unfortunately, longitudinal data
TABLE 2 Key Studies Using CMR to Characterize Potential Mechanisms of Uremic Cardiomyopathy
Cellular Mechanism Study Population Study Type Outcomes First Author (Ref. #)
Renin-angiotensin-
aldosterone system
Aldosterone and
angiotensin II
CRIB-2 study,
nondiabetic
CKD stage 2–4
(n ¼ 112)
Randomized
controlled
trial
After 40 weeks of treatment, signiﬁcant reductions
in both LV mass on CMR and PWV were seen in
the spironolactone group
Edwards et al. (21)
CKD stage 2–4
(n ¼ 70)
Cross-sectional Excretion of urinary mineralocorticoids in CKD
predicts LVMI on CMR; this relationship is
not present in hypertension and supports
altered regulatory RAAS mechanisms
(aldosterone escape)
McQuarrie et al. (52)
Mineral bone disease
Bone density/aortic
calciﬁcation
Nondiabetic CKD
stage 3
(n ¼ 120)
Cross-sectional LV mass was highest in patients with low bone
density and aortic calciﬁcation
Chue et al. (24)
Calcium ESRD on
hemodialysis
(n ¼ 246)
Observational Calcium phosphate product independently predicted
LVMI and LVH; other key predictors were
pre-dialysis SBP and end-diastolic LV volumes
Patel et al. (18)
Phosphate Nondiabetic CKD
stage 2–4
(n ¼ 208)
Cross-sectional Serum phosphate was independently associated
with LV mass
Chue et al. (16)
Nondiabetic CKD
stage 3
(n ¼ 120)
Randomized
controlled trial
After 40 weeks, there were no differences between
sevelamer and placebo groups with regard to LV
mass, systolic and diastolic function, or pulsed
wave velocity
Chue et al. (52)
FGF-23 Diabetic, IgA
nephropathy
CKD stage 3–4
(n ¼ 48)
Cross-sectional FGF-23 was elevated and was an independent
predictor of LVH in CKD but not in essential
hypertension
Stevens et al. (22)
Vitamin D PRIMO study, CKD
stage 2–4
(n ¼ 227)
Randomized
controlled
trial
Therapy for 48 weeks with active vitamin D did
not reduce LV mass on CMR imaging or improve
LV diastolic function on echocardiography
Thadhani et al. (25)
Purine metabolism
Uric acid CKD stage 3 with
LVH (n ¼ 53)
Randomized
controlled trial
After 9 months of treatment, allopurinol signiﬁcantly
reduced LVMI and improved augmentation index
and endothelial function by FMD independent of a
change in BP; changes in FMD and proteinuria
were both independent predictors for a change
in LVMI
Kao et al. (53)
Collagen/ﬁbrosis
Collagen turnover CRIB-2 study,
nondiabetic
CKD stage 2–4
(n ¼ 112)
Randomized
controlled trial
Spironolactone treatment attenuated an increase in
PIIINP levels associated with impairment of LV
diastolic function
Edwards et al. (53)
Myocardial ﬁbrosis ESRD on RRT
(n ¼ 134)
Observational Subendocardial infarction in 14% was associated
with conventional CV risk factors; mid-wall diffuse
ﬁbrosis in 14% associated with LV mass but not
conventional atheromatous risk factors
Mark et al. (9)
Continued on the next page
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706on LV remodeling during progression of CKD and
in response to treatment are scarce.
A key question in relation to the high prevalence
of LVH in CKD is whether this association is purely
the result of elevated blood pressure. Although
blood pressure may be one important determinant, it
does not appear to be the sole driving force behind
the development of UC (18). For example, an inde-
pendent association exists between urinary protein
excretion and LV mass on CMR that is also inde-
pendent of blood pressure (19). Moreover, the varia-
tions in response to different antihypertensive
agents suggest that other, blood pressure–independent mechanisms are involved (20). Aldo-
sterone may be a major driver of this process (21), and
mediators of abnormal bone mineral metabolism in
CKD may also be important. Serum phosphate level
has been shown to predict LV mass independently of
renal function and blood pressure (16,18). This may be
mediated by increased arterial stiffness, which is
common in CKD. Increased levels of the phosphaturic
hormones ﬁbroblast growth factor 23 (FGF-23) and
parathyroid hormone arising from impaired renal
excretion of phosphate are also implicated (22). These
intermediaries have been shown to induce myocyte
hypertrophy in vitro and in animal studies (23).
TABLE 2 Continued
Cellular Mechanism Study Population Study Type Outcomes First Author (Ref. #)
Proteinuria
Proteinuria CKD stage 2–4
(n ¼ 49)
Observational Spot protein/creatinine ratio and 24-h proteinuria
both independently predicted LVMI on CMR in
diabetic patients; combined with SBP, proteinuria
accounted for 29% and 23% variation in LV mass,
respectively.
McQuarrie et al. (54)
CKD stage 2–4
(n ¼ 70)
Cross-sectional Proteinuria was a univariate predictor of LVMI; urinary
aldosterone independently predicted proteinuria
and was associated with elevated urinary sodium
levels (surrogate of dietary sodium intake); these
data support altered RAAS regulation
McQuarrie et al. (52)
Arterial stiffness
CKD stage 5
(n ¼ 144)
Observational Aortic distensibility on CMR was negatively correlated
with LV mass, was lower in patients with nonfatal
CV events, and was an independent predictor of
mortality (with SBP and diabetes) over median
follow-up of 719 days
Mark et al. (43)
ESRD  CAD
(n ¼ 35)
Cross-sectional Patients with ESRD without CAD had reduced aortic
compliance to an equivalent level as patients
with severe CAD awaiting coronary bypass
surgery; these data support an alteration
in the ﬁbroelastic composition within the
arterial wall as a cause for altered arterial-
ventricular interaction in ESRD
Zimmerli et al. (42)
Nondiabetic
CKD stage
2–3 (n ¼ 189)
Cross-sectional Aortic distensibility was signiﬁcantly reduced a
different levels throughout the thoracic aorta
compared with control subjects; the strong
independent predictors were age and GFR,
which accounted for 50% of variation in the
ascending aorta
Chue et al. (44)
The cellular pathophysiological mechanisms promoting uremic cardiomyopathy in ESRD were previously reviewed by Glassock et al. (51). Please see the Online Appendix for additional
references.
BP ¼ blood pressure; CAD ¼ coronary artery disease; CKD ¼ chronic kidney disease; CMR ¼ cardiac magnetic resonance; CV ¼ cardiovascular; ESRD ¼ end-stage renal disease; GFR ¼
glomerular ﬁltration rate; FGF ¼ ﬁbroblast growth factor; FMD ¼ ﬂow mediated dilatation; IgA ¼ immunoglobulin A; LV ¼ left ventricular; LVH ¼ left ventricular hypertrophy; LVMI ¼ left
ventricular mass index, PIIINP ¼ aminoterminal propeptide of type III procollagen; PWV ¼ pulsed wave velocity; RAAS ¼ renin-angiotensin-aldosterone system; RRT ¼ renal replacement
therapy; SBP ¼ systolic blood pressure.
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707Finally, experiments in vitro have demonstrated
that high levels of intracellular phosphate actively
promote the osteogenic transformation of vascular
smooth muscle cells and result in vascular calciﬁca-
tion. Consistent with this ﬁnding, the presence of
aortic calciﬁcation is associated with increased arte-
rial stiffness and CMR-measured LV mass (24). More
recent data, however, assessing the effect of phos-
phate binder and vitamin D therapy on LV mass
regression after 40 and 48 weeks, respectively, in
stage 3 and 4 CKD, were negative (25).
CHARACTERIZING THE PATHOGENESIS OF
UREMIC CARDIOMYOPATHY WITH CMR
Characterization of myocardial tissue using Gd-based
contrast agents is a major strength of CMR and has
been applied in CKD to elucidate further the struc-
tural changes that are found. In a cross-sectional
study, 28% of patients with ESRD had evidence of
late Gd enhancement (LGE), 72% had LVH on CMR,
and the average blood pressure of the whole cohortwas 139/81 mm Hg (9). One-half of these patients (14%
of the total) had discrete subendocardial LGE
indicative of myocardial infarction (Fig. 2A), the
presence of which was associated with a history of
ischemic heart disease and conventional cardiovas-
cular risk factors including hypercholesterolemia and
diabetes (but not hypertension). The other patients
with LGE had diffuse mid-wall scarring (Fig. 2B),
which was associated with greater LV mass but not
with risk factors for coronary atheroma, LV systolic
dysfunction, or angiographic coronary artery disease.
The etiology of this pattern of ﬁbrosis in CKD remains
unclear. In a smaller study of 24 patients undergoing
hemodialysis, LGE was found in 79%, once again
divided not only into an infarct-related pattern but
also into diffuse and focal noninfarct patterns in
equal percentages (26). This study differed from that
of Mark et al. by including only patients undergoing
hemodialysis and also by studying a high proportion
of African-American patients. Although LV mass was
much higher in the latter group, both studies
identiﬁed a signiﬁcant relationship between volume
TABLE 3 Complementary Imaging Techniques Used to Assess the Cardiovascular Features of Uremic Cardiomyopathy
Imaging Features
Imaging Technique: Strengths and Limitations
2D Echocardiography/Ultrasonography Comment Cardiac Magnetic Resonance Comment
LV structure
LV mass M-mode or 2D Increased interstudy and operator
variability
LV geometric assumptions
Volume dependent
Image quality
Short-axis LV contouring Reference standard
High reproducibility
No geometric assumptions
Load independent
LV dilation M-mode or 2D dimensions or volumes Load dependent Short-axis LV contouring: endocardial
segmentation and summation of disks
High reproducibility
No geometric assumptions
Load independent
LV function
Global LV ejection fraction As per LV mass LV ejection fraction As per LV mass
Regional Deformation imaging (strain, torsion) High temporal resolution
Angle independent (Speckle tracking)
Strain is load dependent
Image quality
Deformation imaging (myocardial
tissue tagging)
Reference standard
Improvements in tag-tissue contrast
and persistence
Improving temporal resolution (15–20 ms)
Longitudinal Long-axis function (tissue
Doppler imaging)
High temporal resolution
Heart rate and load dependent
Phase contrast myocardial tissue velocities
Annular plane excursion
Lower temporal resolution than echo
Diastolic Transmitral and pulmonary venous
Doppler indices
LA volumes (biplane area-length)
High temporal resolution
Heart rate dependent
Load dependent
Geometric assumptions
Phase contrast transmitral and pulmonary
venous ﬂow
Short-axis LA contouring
Lower temporal resolution than echo
Reference standard
No geometric assumptions
Myocardial ﬁbrosis
Integrated backscatter Validation against histological collagen
content
Assessment of interstitial ﬁbrosis
Wide availability
Low reproducibility
Late gadolinium enhancement
T1 mapping
Reference standard
Histological validation
Limited to detection of coarse scarring
Use may be precluded in ESRD
Detection of diffuse ﬁbrosis
New noncontrast techniques
Arterial function
Arterial stiffness Aortic distensibility, aortic compliance,
b-index on high-deﬁnition echo-tracking
and ultrasound devices
Carotid-femoral PWV
Noninvasive blood pressure
measurements for central
hemodynamics
Lower spatial resolution
Reference standard
Aortic distensibility
PWV
Direct assessment
Assessment of multiple arterial sites
Noninvasive blood pressure measurements
for central hemodynamics
Endothelial
dysfunction
Flow-mediated dilation Reference standard
Correlation with invasive coronary
artery assessment.
Complementary assessment of
ﬂow-mediated constriction
Brachial artery dilation High spatial resolution, direct quantiﬁcation
Assessment of central and peripheral arteries
Integrated assessment of vascular and ventricular
function in a single examination
2D ¼ 2-dimensional; LA ¼ left atrial; LV ¼ left ventricular; PWV ¼ pulsed wave velocity.
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FIGURE 1 Assessment of LV Mass in CKD With CMR and Transthoracic Echocardiography
(A) Short-axis stack of a patient with stage 4 chronic kidney disease (CKD) who was diagnosed with left ventricular (LV) hypertrophy on
transthoracic echocardiography (maximum wall thickness, 15 mm; LV mass, 129 g/m2) but within normal limits for sex and age on cardiac
magnetic resonance (CMR) (maximum wall thickness, 12 mm; LV mass, 84 g/m2). (B) Bland-Altman analysis of the difference in LV mass
measured by echocardiography and CMR in patients undergoing hemodialysis. M-mode echocardiography (Echo) signiﬁcantly overestimates
LV mass relative to CMR as mass increases. MR ¼ magnetic resonance. (B) Adapted with permission from Stewart et al. (8).
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709of LGE and LV mass. The prevalence of LGE in early-
stage CKD is unclear, but LGE appears to be far less
common. In a cross-sectional study of 100 patients
with stage 2 and 3 CKD but no history of
cardiovascular disease and low levels of risk factors,
only 6% had mid-wall diffuse LGE, and 1% had
subendocardial enhancement consistent with a
previous silent myocardial infarction (27). Unlike the
studies of LGE in ESRD, these patients had normal
LV mass, but the predominance of patients with
vasculitic disease suggested that inﬂammation may
be important in this process.
The implication of these studies is that ESRD is
characterized either by infarct-related scar (driven by
atheroma) or by coarse focal scarring that is related
directly to the severity of LV hypertrophy. No direct
histological veriﬁcation of the cause of LGE-CMR in
CKD has been reported, but the ﬁndings are consis-
tent with myocardial biopsy results from patients
with ESRD that demonstrate severe myocyte hyper-
trophy, myocyte disarray, and extensive interstitial
ﬁbrosis (28). These biopsy studies contrast with the
histological ﬁndings in arterial hypertension and
diabetes, in which accumulation of type I and type III
collagen ﬁbers most commonly results in reactive
interstitial ﬁbrosis with diffuse distribution within
the interstitium. Such diffuse ﬁbrosis is often missed
on LGE CMR because this technique relies on relativedifferences in signal intensities and employs the
myocardium with the lowest signal intensity as a
reference for normality, regardless of the degree of
ﬁbrosis therein (29). Although LGE is found in some
patients with arterial hypertension, the relationship
between the extent of LGE scar and the severity of LV
hypertrophy that is observed in CKD is not (30).
Newer T1 mapping techniques hold great promise in
investigating the interactions among hypertension,
CKD, and the development of ventricular dysfunction
and subsequent clinical events.
VENTRICULAR FUNCTION IN
UREMIC CARDIOMYOPATHY
Despite the frequency of LVH, focal myocardial
ﬁbrosis, and infarct-related disease, overt systolic
dysfunction is uncommon in pre-dialysis CKD. In the
cross-sectional study of pre-dialysis patients by Park
et al. (15), only 8% had systolic dysfunction (deﬁned
as an ejection fraction <45%), and no association was
noted between kidney function (eGFR) or the level of
proteinuria and systolic function in demographic or
multivariate models. This is the same rate as found on
CMR in patients undergoing dialysis when using an
LV ejection fraction cut-off below 55% (9). At ﬁrst,
this ﬁnding appears at odds with the known rates of
sudden cardiac death, arrhythmia, and heart failure,
FIGURE 2 Examples of LGE Imaging in Patients With CKD
(A) An infarct-related pattern of late gadolinium enhancement (LGE) (arrows)
in a patient with stage 3 chronic kidney disease (CKD), without a known his-
tory of coronary heart disease. (B) Non–infarct-related diffuse pattern
(arrows) on LGE in the basal lateral wall of a patient with stage 3 CKD.
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710but on further consideration, it serves to emphasize
the limitations of using ejection fraction to quantify
LV function, particularly in a population exposed to
large variations in loading conditions.
The application of newer imaging techniques to
assess systolic and diastolic function in CKD suggests
that the extent and severity of functional abnormal-
ities were previously underestimated (31). Using tis-
sue Doppler echocardiography in 129 patients with
ESRD (62% undergoing dialysis) with a normal LV
mass and without evidence of myocardial ischemia
or overt LV dysfunction (mean LV ejection fraction,
59%), Rahkit et al. (31) demonstrated that at least
one marker of reduction in either LV deformation or
early myocardial relaxation velocity was present in
all patients. Moreover, these changes independently
predicted an increase in all-cause mortality and
cardiac mortality over 2.4 years of follow-up (31). A
similar reduction in LV deformation was also evident
on tissue Doppler echocardiography in patients with
stage 2 and 3 CKD (32). The advantages of CMR tissue
tagging over tissue Doppler echocardiography are
well known, and use of this technique has extended
these ﬁndings. Using spatial magnetization modula-
tion tissue tagging, it has been possible to show
that reduction in strain and strain rate is conﬁned
not only to longitudinal myocardial shorteningbut also to circumferential contraction in stage 2
and 3 CKD, speciﬁcally affecting the mid-wall and
endocardium compared with control subjects (Fig. 3)
(33). The circumferential abnormalities differ from
those observed with aging, hypertension, and heart
failure with preserved ejection fraction, a ﬁnding
conﬁrmed in a study of 98 patients who were receiv-
ing maintenance hemodialysis, and may suggest a
different pathophysiological process in CKD (34).
Taken together, these studies suggest that LV function
is abnormal from the early stages of CKD and that re-
duction in LV ejection fraction is a late feature of UC.
Right ventricular function is a powerful indepen-
dent predictor of outcome in heart failure in the
general population, and some evidence indicates a
relationship with outcome in patients with CKD and
LV systolic heart failure (35). Studies of the interac-
tion between CKD and right ventricular structure
and function are limited to patients with ESRD
who have been studied with TTE, mainly by investi-
gating the effect on tissue velocity imaging and long-
axis function measured by tricuspid annular plane
systolic excursion (36). The difﬁculty in using these
data in CKD is that such measures are load depen-
dent, and the prevalence of pulmonary hypertension
in ESRD may be as high as 60% (37). Assessment of
right ventricular structure and function is a unique
strength of CMR, and studies are awaited that in-
vestigate both cross-sectional change according to
severity of CKD and longitudinal outcome.
ASSESSMENT OF ARTERIAL STIFFNESS BY CMR:
A PRECURSOR TO UREMIC CARDIOMYOPATHY?
CKD is characterized by a high prevalence of
atheroma, but of equal importance is arteriosclerosis.
This different arterial disease affects the medial
layer of the arterial wall and is characterized by
thickening (increased collagen and smooth muscle
hypertrophy) and calciﬁcation (38). The resultant in-
crease in arterial stiffness and loss of arterial disten-
sibility exposes the myocardium, brain, and kidneys
to higher pressure ﬂuctuations and is a strong pre-
dictor of cardiovascular morbidity and mortality in
ESRD (39). There is a graded increase in arterial
stiffness that occurs with advancing stages of CKD
(40) and is independent of blood pressure and aging,
thus leading investigators to hypothesize that arterial
stiffness is intimately linked to UC (41).
To date, most of the data on arterial stiffness in
CKD have been derived from applanation tonometry
techniques to measure pulsed wave velocity. CMR,
however, allows complete assessment of arterial
function through measurement of aortic distensibility
FIGURE 3 Examples of CMR Tissue Tagging for Deformation Assessment
(A) Short-axis images in end-diastole, mid-systole, and end-systole with spatial magnetization modulation tissue tagging for assessment of
circumferential deformation using Cardiac Image Modeller software (CIM-Tag; University of Auckland, Auckland, New Zealand). (B) Longitu-
dinal tagging assessment of the left ventricle in a 4-chamber view. CMR ¼ cardiac magnetic resonance.
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711(AD), aortic pulsed wave velocity, and endothelial
function by brachial artery ﬂow-mediated dilation
(Fig. 4). In a small cross-sectional study, 24 patients
who were undergoing dialysis and who did not have
coronary artery disease (angiography or exercise
testing) were compared with age- and sex-matched
patients who had severe CAD and who were awaiting
bypass, as well as with healthy control subjects
(42). Aortic compliance in the ascending aorta was
reduced to equivalent levels in patients with ESRD
and coronary artery disease. The prognostic impor-
tance of reduced AD in ESRD was highlighted in a
study of 144 patients with stage 5 CKD (76% un-
dergoing dialysis) (43). Over a median follow-up
of 24 months, AD and aortic volumetric arterial
strain (a non–pressure-dependent parameter) were
independent predictors of combined vascular events
and mortality, whereas AD also predicted all-cause
mortality.
AD is reduced early in CKD. In a cross-sectional
study of 189 patients with nondiabetic stage 2 to 4
CKD, AD in the proximal and descending thoracic
aorta was reduced with a graded relationship to eGFR
(r ¼ 0.172, p < 0.01) (44). Both age and eGFR inde-
pendently predicted AD in the ascending aorta,
thereby explaining 50% of variance. Similar trendswere seen in a study in stage 2 and 3 disease in which
AD in the ascending aorta was also inversely corre-
lated with LV mass (r ¼ 0.284, p < 0.01). In regres-
sion analysis, AD contributed 6% of the variance in
LV mass index, and this compared to 2% for GFR and
10% for systolic blood pressure (17). These changes in
large arterial function are thought to be closely linked
to the development of UC: as arterial stiffness in-
creases, the loss of AD exposes the myocardium to
higher systolic pressures and greater pressure ﬂuc-
tuations (38). Although high systolic pressure in-
creases afterload, lower diastolic pressure reduces
diastolic coronary perfusion and promotes coronary
microvascular ischemia. In health and early CKD,
cardiac function is matched to arterial function to
ensure maximum cardiac efﬁciency, a relationship
demonstrated on TTE as the ratio of arterial to ven-
tricular elastance (17). Whereas the arterial-to-
ventricular coupling ratio is preserved in CKD,
absolute levels of arterial and ventricular stiffness
are increased. Thus cardiac reserve is reduced, but
at a price: diastolic relaxation is impaired, and
left atrial volumes are elevated (45). Inefﬁciency
in cardiac energetic metabolism also is found in
patients with ESRD, as measured using phosphorus-
31 magnetic resonance spectroscopy (46).
FIGURE 4 Examples of Arterial Assessment on CMR
(A) Pulsed wave analysis in the thoracic aorta. The intercept method of the upstroke in the ascending aorta (Asc Ao) and descending aorta (Desc
Ao) are used to calculate transit time between the two sites. Distance is assessed through the midline of the aortic lumen on a sagittal oblique
image. Pulsed wave velocity is calculated as distance/time. (B) Distensibility in the ascending aorta. The maximal and minimal areas are applied
to a formula with simultaneously acquired brachial blood pressure to calculate aortic distensibility. (C) Brachial artery reactivity to hyperemia. A
pressure cuff is applied to the forearm distal to the imaging site, and a surface coil placed is placed above the elbow region. The middle panel
shows high-resolution magnetic resonance imaging aligned perpendicular to the brachial artery (arrow). CMR ¼ cardiac magnetic resonance.
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712CONTRAST-ASSOCIATED NEPHROGENIC
SYSTEMIC FIBROSIS: AN END TO FIBROSIS
RESEARCH IN END-STAGE RENAL DISEASE?
The safety of contrast-enhanced magnetic resonance
imaging using Gd-based agents in CKD was chal-
lenged in 2006 when a link between nephrogenic
systemic ﬁbrosis (NSF) and Gd-based contrast agents
emerged from a registry of 355 cases that all occurred
in patients with ESRD. Patients with NSF present with
indurated plaques and papules on the distal extrem-
ities caused by deposition of collagen bundles in the
dermis with resultant hardened skin; in 5% cases,
this condition progresses to stiffness, joint contrac-
tures, and ultimately internal organ involvement
(47). No effective treatment is known, although NSF
can be improved by restoration of normal renal
function. Gd itself is toxic, but these adverse effects
are suppressed in clinical use by encasing it withina chelator, which may be linear or cyclic. Over time,
Gd may dissociate from the chelate, but in subjects
with normal renal function, this happens too slowly
for tissue to be exposed to the toxic effects of the
metal. Most Gd-based contrast agents are renally
excreted, and the half-life may be increased from
90 min with normal renal function to up to 18 to
34 hours in ESRD, which may be sufﬁcient for
release of Gd from linear chelates. The risk of NSF
appears to be increased synergistically with a recent
proinﬂammatory event, such as surgery, and with
sepsis (48). Risk also depends on the type of contrast
agent (most cases have occurred with nonionic linear
chelates) and the dose used; the incidence is near
zero at 0.1 mmol/kg regardless of renal function (49).
Following the introduction of a series of European
and American guidelines, virtually no new cases of
NSF have been reported in patients either with
normal renal function or CKD (49). Caution is now
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713advised in patients with eGFR <30 ml/min/1.73 m2,
and recent assessment of renal function is obligatory.
If CMR with Gd-based contrast agents is still thought
necessary, low-risk agents (gadobutrol, gadoteridol,
and gadoterate) should be used at the lowest
possible dose (0.1 mmol/kg perfusion; 0.1 to 0.2
mmol/kg LGE) with early dialysis after imaging.
Under these circumstances, the risk of NSF appears
to be very low (47).
CONCLUSIONS
CMR has a proven role in patients with both early-
stage and end-stage CKD in deﬁning LV mass and
subclinical and overt ventricular dysfunction and in
identifying the presence of coarse ﬁbrosis. Future
research is needed using CMR to conﬁrm the ﬁndings
of existing case-control studies with longitudinal
outcome follow-up. It will be important to identify
the impact of LGE ﬁbrosis on outcome, but perhapsgreater opportunity lies with the development of
extracellular volume T1 mapping, which may open
the way to intervention studies to reverse the huge
impact of cardiovascular morbidity and mortality in
this common condition. As part of this process, ani-
mal and human translational work is required to
conﬁrm the histological foundation of cardiovascular
ﬁbrosis in CKD.
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